Nutritional Supplement for Patients With Severe Infection (NUWISE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lynda Lazosky
- Phone Number: 778-389-9074
- Email: llazosky@providencehealth.bc.ca
Study Contact Backup
- Name: Niki Boyd, PhD
- Email: boyd.niki@gmail.com
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, v6k 2a8
- Recruiting
- St Paul's Hospital
-
Contact:
- john boyd
- Phone Number: 6047106713
- Email: john.boyd@hli.ubc.ca
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of Sepsis
- plasma high density lipoprotein levels less than 1 mM
- receiving enteral nutrition
Exclusion Criteria:
• known pregnancy/intending to get pregnant within 28 days of enrollment in study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Lauric Acid and Berberine
Participants in this arm of the trial will receive 15 ml lauric acid and 1000 mg berberine daily (via feed tube) for the duration of time that they are receiving enteral feeding, up to a maximum time of 14 days
|
intervention (15 ml lauric acid + 1000 mg berberine) will be provided daily to participants in this arm for the duration of time that they receive enteral nutrition for a period of 14 days maximum
|
|
No Intervention: No-intervention
participants in this arm will receive no additional intervention, beyond standard of care
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma HDL
Time Frame: 14 days
|
Maximum Plasma Concentration [Cmax] HDL (mmol)
|
14 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
WBC
Time Frame: 14 days
|
Absolute count (cells per microliter)
|
14 days
|
|
Cytokines
Time Frame: 14 days
|
Maximum Plasma Concentration [Cmax] plasma IL-6, IL-8, IL-10
|
14 days
|
|
28-day survival
Time Frame: 28 days
|
28-day survival
|
28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- H21-00109
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.